Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (Diabetes, Obesity & Metabolism)
the retina and kidney are mainly affected by microvasculopathy (Fig
Maximum results are typically seen at 16-24 weeks of consistent daily supplementation
This Product is not intended to diagnose, treat, cure or prevent any disease
NAD+ and glutathione levels are influenced by how you live your life every day
Injection burden 1-2 injections per day on overlap days Best for Metabolic + mitochondrial pairing Cycle driver Retatrutide titration sets the pace Retatrutide Loading 1 2 4 6 9 mg (every 4 weeks) Frequency Once weekly Maintenance 9 mg or 12 mg weekly Route SubQ MOTS-c (intermittent - most common) Loading Start Week 5: 5 mg, 2x weekly Frequency 2-3x weekly Maintenance 5-10 mg, 2-3x weekly Route SubQ MOTS-c (low-dose daily - alternative) Loading Start Week 5: 200 mcg/day, +200 mcg every 2 weeks Frequency Daily Maintenance Up to 1 mg daily Route SubQ Weekly Schedule Example - Intermittent MOTS-c (Weeks 5-16) Monday Retatrutide 2 mg (morning) + MOTS-c 5 mg (pre-training) Tuesday Rest day Wednesday MOTS-c 5 mg (pre-training) Thursday Rest day Friday MOTS-c 5 mg (pre-training) Saturday Rest day Sunday Rest day Community protocols use different injection sites and separate syringes when both compounds are dosed the same day
